<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02097693</url>
  </required_header>
  <id_info>
    <org_study_id>Uni-Koeln-1603</org_study_id>
    <nct_id>NCT02097693</nct_id>
  </id_info>
  <brief_title>Effect of DBS on Quality of Life in Dyskinetic Cerebral Palsy</brief_title>
  <acronym>STIM-CP</acronym>
  <official_title>Effect of Deep Brain Stimulation in the Globus Pallidus Internus on Quality of Life in Young Patients With Dyston-dyskinetic Cerebral Palsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital of Cologne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital Schleswig Holstein Campus Luebeck</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hsopital of Magdeburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital of Munich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Schoen Klinik Vogtareuth</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital of Tübingen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital of Duesseldorf</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hannover Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital of Kiel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital of Würzburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital of Freiburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Berlin Charite</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital of Cologne</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There are limited therapeutical options for patients with secondary dystonia due to cerebral&#xD;
      palsy. Pharmacotherapy is often without effect, or side effects are severe. Meanwhile deep&#xD;
      brain stimulation (DBS) has proven to be a safe and effective therapy for patients with&#xD;
      parkinson´s disease or primary / idiopathic dystonia. Experiences with DBS in patients with&#xD;
      dyskinetic cerebral palsy are limited with heterogeneous data.&#xD;
&#xD;
      With STIM-CP we investigate the effect of DBS on quality of life in young patients with a&#xD;
      dyskinetic movement disorder (dyskinetic cerebral palsy) due to perinatal hypoxic brain&#xD;
      injury. Additionally, the effect of DBS on motor development, speech, memory, attention,&#xD;
      cognition and pain perception will be assessed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In total, 20 patients aged 7-18 years diagnosed with dyskinetic cerebral palsy due to&#xD;
      perinatal asphyxia, who will receive DBS, should be included. 11 German DBS-centres will&#xD;
      participate in the trial. Effects of DBS will be assessed up to 36 months after Initial&#xD;
      Implantation.&#xD;
&#xD;
      There are two preoperative visits (screening and baseline) and nine postoperative visits&#xD;
      (implantation, 3-, 6-, 9-, 12-, 24- and 36-moths follow-up). We assume that DBS reduces the&#xD;
      severity of dystonia and improves the quality of life in these patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 4, 2014</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Actual">March 10, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Caregiver Priorities and Child Health Index of Life with Disabilities (CPCHILD)</measure>
    <time_frame>CPCHILD 12 months after DBS</time_frame>
    <description>Difference in CPCHILD before and 36 months on DBS (response=improvement &gt; 10%)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Burke-Fahn-Marsden-Dystonia Rating Scale movement and disability</measure>
    <time_frame>0, 6, 12, 24 and 36 months after DBS</time_frame>
    <description>Assessment of the severity of dystonia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyskinesia Impairment Scale</measure>
    <time_frame>0, 12, 24 and 36 months</time_frame>
    <description>Assessment of the severity of chorea and dystonia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tardieu Scale</measure>
    <time_frame>0 and 12 months after DBS</time_frame>
    <description>Assessment of the severity of spasticity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frenchay Dysarthria Assessment</measure>
    <time_frame>0, 12, 24 and 36 months after DBS</time_frame>
    <description>Assessment of speech and swallowing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36</measure>
    <time_frame>0, 6, 12, 24 and 36 months after DBS</time_frame>
    <description>Assessment of Quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Strengths and Difficulties Questionnaire</measure>
    <time_frame>0, 6, 12, 24 and 36 months after DBS</time_frame>
    <description>Assessment of mood and attention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Snijders-Oomen-Non-Verbal-Intelligence Test (SON-R)</measure>
    <time_frame>0 and 12 months</time_frame>
    <description>Assessment of Cognition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Attentional Network Test (ANT)</measure>
    <time_frame>0 and 12 months after DBS</time_frame>
    <description>Assessment of Attention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-Verbal-Learning Test (NVLT)</measure>
    <time_frame>0 and 12 months after DBS</time_frame>
    <description>Assessment of cognition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wong Baker Faces</measure>
    <time_frame>0, 6, 12, 24 and 36 months after DBS</time_frame>
    <description>Assessment of pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Family Scale (FaBel)</measure>
    <time_frame>0, 6, 12, 24 and 36 months after DBS</time_frame>
    <description>Assessment of the burden for caregivers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CPCHILD</measure>
    <time_frame>0, 6, 24 and 36 months after DBS</time_frame>
    <description>Assessment of quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Canadian Occupational Performance Measure (COPM)</measure>
    <time_frame>COPM 0 and 12 months after DBS</time_frame>
    <description>Assessment of activities of daily living</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gross Motor Function Measure (GMFM-66)</measure>
    <time_frame>GMFM-66 0 and 12 months after DBS</time_frame>
    <description>Assessment of physical disability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gross Motor Function Classification System (GMFCS)</measure>
    <time_frame>GMFCS 0, 12, 24 and 36 months after DBS</time_frame>
    <description>Degree of physical impairment</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">16</enrollment>
  <condition>Dyskinetic Cerebral Palsy Due to Perinatal Hypoxia</condition>
  <arm_group>
    <arm_group_label>dyston-dyskinetic cerebral palsy</arm_group_label>
    <description>Young patients with dyston-dyskinetic cerebral palsy who receive DBS in the GPi</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      EDTA-plasma for DYT1-testing&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        primary care clinic&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The treating physician has chosen GPi-DBS for the treatment of the secondary dystonia&#xD;
             caused by cere-bral palsy in this patient&#xD;
&#xD;
          -  Patient and/or legal representative, if the patient is underaged or not capable to&#xD;
             give consent himself, have chosen GPi-DBS as treatment&#xD;
&#xD;
          -  The consent to participate in the trial of the underaged patient, if he is capable to&#xD;
             understand the study requirements, is required&#xD;
&#xD;
          -  Age at enrolment 7-18 years&#xD;
&#xD;
          -  Diagnosis of secondary dystonia due to cerebral palsy caused by perinatal hypoxic&#xD;
             injury&#xD;
&#xD;
          -  Anti-dystonic pharmacotherapy insufficient (e.g. Jankovic J. Medical treatment of&#xD;
             dystonia. Movement disorders, Vol. 28, No. 7, 2013) 67&#xD;
&#xD;
          -  Stable anti-dystonic medication over the last 30 days&#xD;
&#xD;
          -  Globus pallidus internus (pars posterior) and thalamus (motor part) intact on MRI (not&#xD;
             older than 2 years - if possible)&#xD;
&#xD;
          -  No fixed severe skeletal deformations with loss of function, which need immediate&#xD;
             orthopaedic surgical intervention&#xD;
&#xD;
          -  Sufficient compliance of the patient or the legal representative if the patient is&#xD;
             underaged or not capable to give consent himself to take part in the study&#xD;
&#xD;
          -  Informed consent to take part in the study from patient and/or legal representative if&#xD;
             the patient is underaged or not capable to give consent himself&#xD;
&#xD;
          -  Patient and/or legal representative if the patient is underaged or not capable to give&#xD;
             consent himself, understands the study requirements and the treatment procedures and&#xD;
             provides written informed consent before any study-specific tests or procedures are&#xD;
             performed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  • Patients with known primary (e.g. DYT1) or idiopathic dystonia&#xD;
&#xD;
               -  Severe axial hypotonia with total loss of head control (e.g. absence of control&#xD;
                  at &quot;upper thoracic level&quot; in the SATCo score) (medication effect excluded)&#xD;
&#xD;
               -  Fixed hemi-dystonia&#xD;
&#xD;
               -  Severe spasticity in knee- and elbow-flexors and -extensors (Modified Ashworth&#xD;
                  Scale &gt;3)&#xD;
&#xD;
               -  Fixed severe skeletal contractions with loss of function which require immediate&#xD;
                  orthopaedic surgical intervention&#xD;
&#xD;
               -  Patients with other severe concurrent neurological disease (e. g. brain tumor,&#xD;
                  neurodegenerative diseases, trauma etc.)&#xD;
&#xD;
               -  Condition likely to require use of MRI in the future&#xD;
&#xD;
               -  Any intracranial abnormality or medical condition that would contraindicate DBS&#xD;
                  surgery&#xD;
&#xD;
               -  Any findings in neuropsychological screening assessments that would&#xD;
                  contraindicate DBS surgery&#xD;
&#xD;
               -  Any current drug and / or alcohol abuse&#xD;
&#xD;
               -  Any history of frequent grand-mal seizures without response to anticonvulsive&#xD;
                  treatment&#xD;
&#xD;
               -  Any other active implanted device (e.g. Cochlear implant, pacemaker), whether&#xD;
                  turned on or off, would be allowed provided that they do not interfere with&#xD;
                  functioning of the device.&#xD;
&#xD;
               -  Any previous brain surgery that would interfere with the placement of the leads&#xD;
                  or the functioning of the device.&#xD;
&#xD;
               -  A history of neurostimulation intolerance in any area of the body.&#xD;
&#xD;
               -  Currently on any anticoagulant medications that cannot be discontinued during&#xD;
                  perioperative period.&#xD;
&#xD;
               -  Any significant medical condition that is likely to interfere with study&#xD;
                  procedures or likely to confound evaluation of study endpoints, including any&#xD;
                  terminal illness with survival &lt;12 months.&#xD;
&#xD;
               -  Participation in another drug, device, or biologics trial concurrently or within&#xD;
                  the preceding 30 days; any other trial participation should be approved by the&#xD;
                  Principal Investigator.&#xD;
&#xD;
               -  A female that is breastfeeding or of child bearing potential with a positive&#xD;
                  urine pregnancy test or - if a person is sexually active - not using sufficient&#xD;
                  contraception with a Pearl Index of less than 1% including all forms of hormonal&#xD;
                  contraception (&quot;antibaby-pill&quot;, hormonal plaster, NuvaRing®, Implanon®, hormonal&#xD;
                  depot injections, contraceptive coil), the tubal ligature (female sterilization).&#xD;
                  Alternatively, the female of child bearing potential is sexually abstinent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne Koy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Cologne, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Cologne</name>
      <address>
        <city>Cologne</city>
        <state>Northern Westfalia</state>
        <zip>50935</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 24, 2014</study_first_submitted>
  <study_first_submitted_qc>March 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2014</study_first_posted>
  <last_update_submitted>May 18, 2021</last_update_submitted>
  <last_update_submitted_qc>May 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cologne</investigator_affiliation>
    <investigator_full_name>Anne Koy</investigator_full_name>
    <investigator_title>Priv.-Doz. Dr. med. Anne Koy</investigator_title>
  </responsible_party>
  <keyword>DBS</keyword>
  <keyword>quality of life</keyword>
  <keyword>dystonia</keyword>
  <keyword>dyskinetic cerebral palsy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paralysis</mesh_term>
    <mesh_term>Cerebral Palsy</mesh_term>
    <mesh_term>Hypoxia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

